BCRX vs MMC · rev $374.7M vs P/E 22, rev $26.98B
BioCryst Pharmaceuticals Inc (BCRX) versus Marsh & McLennan Companies Inc (MMC) — a side-by-side from cached financials, not a winner call.
BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on US.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
Latest reported BCRX revenue for 2026-06-30 was $374.7M. Net income was -$643.4M. BCRX currently screens at market cap $1.83B.
Latest reported MMC revenue for 2025-12-31 was $26.98B. Net income was $4.16B. Revenue was up 10.3% from 2024-12-31 to 2025-12-31. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
BCRX currently screens at market cap $1.83B. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
Not investment advice. Open the BCRX and MMC stock pages for the full models.
Not investment advice.